Teleflex Incorporated filed an 8-K current report on November 5, 2026, announcing financial results for the quarter ended September 30, 2026, via a press release and an accompanying earnings conference call slide presentation.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Non-GAAP measures disclosed: The press release includes pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, and adjusted diluted earnings per share alongside GAAP results.
  • Acquisition adjustment: Pro forma adjusted revenue gives effect to the acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.
  • Strategic divestitures referenced: Adjusted diluted EPS excludes separation costs related to agreements to divest the Acute Care, Interventional Urology, and OEM businesses, described in the filing as the "Strategic Divestitures."
  • Italian payback measure: Both pro forma adjusted revenue and adjusted diluted EPS exclude the impact of reserves related to Italian legislation requiring medical device suppliers to make payments when regional expenditure ceilings are exceeded.
  • Conference call and slide presentation: A slide presentation was made available through the company's website in advance of a November 5, 2026 conference call.
  • Signed by: John R. Deren, Executive Vice President and Chief Financial Officer.

Teleflex Discloses Q3 2026 Results with Non-GAAP Adjustments and Strategic Divestiture Context

Teleflex Incorporated (NYSE:TFX) filed an 8-K on November 5, 2026 under Items 2.02 and 7.01, furnishing a press release (Exhibit 99.1) and earnings slide presentation (Exhibit 99.2) related to its third-quarter financial results for the period ended September 30, 2026. According to the filing, the press release includes both GAAP financial information and several non-GAAP measures that management uses "to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons."

The filing describes three non-GAAP measures in detail. Pro forma adjusted revenue adjusts net revenues to exclude, depending on the period, products discontinued in the year ended December 31, 2025 due to a strategic realignment, to give effect to the acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025, and to exclude the impact of Italian payback reserve changes. Pro forma adjusted constant currency revenue growth applies those same adjustments and also eliminates the impact of translating international subsidiary results at differing exchange rates. Adjusted diluted earnings per share excludes up to ten categories of items net of tax, including restructuring charges, impairment charges, acquisition and divestiture-related items, separation costs tied to the Strategic Divestitures, intangible amortization, ERP implementation costs, EU Medical Device Regulation registration expenditures, and tax adjustments.

The filing states that management "does not believe that any of the excluded items are indicative of our underlying core performance or business trends," and cautions that non-GAAP measures "should not be relied upon as a substitute for GAAP financial measures" and "may not be comparable to similarly titled measures used by other companies." Both exhibits are furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as the filing expressly notes.

What Was Disclosed

Teleflex filed an 8-K on November 5, 2026, furnishing its Q3 2026 earnings press release and a conference call slide presentation. The filing describes three non-GAAP measures and their composition, referencing the BIOTRONIK acquisition, Strategic Divestitures, and Italian payback legislation as key adjustments.